The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.
In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
Moderna shares soared as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could ...
Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.
UBS lowered the firm’s price target on Moderna (MRNA) to $96 from $108 and keeps a Buy rating on the shares as part of a broader note on the ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Hosted on MSN12h
Moderna Shares Spike on H5N1 News-What's Next for Investors?Shares of Moderna Inc. (NASDAQ: MRNA) surged over 12% after news of the first confirmed death from the H5N1 bird flu in the ...
Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $55.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback